HERON THERAPEUTICS, INC. /DE/: 10-Q filed 2015-05-08
What HERON THERAPEUTICS, INC. /DE/ reported in its quarterly report filed 2015-05-08 (fiscal Q1 2015): 23 published measures, 48 facts as tagged in accession 0001193125-15-179414.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2015-05-08
- Fiscal period
- fiscal Q1 2015
- Accession
- 0001193125-15-179414 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All HERON THERAPEUTICS, INC. /DE/ filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 59,627,000 | USD | |
| At 2014-12-31 | 76,682,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 48,001,000 | USD | |
| At 2014-12-31 | 63,062,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 55,556,000 | USD | |
| At 2014-12-31 | 72,675,000 | USD | |
| At 2014-03-31 | 57,475,000 | USD | |
| At 2013-12-31 | 72,287,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -20,570,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | -17,538,000 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -19,669,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | -15,713,000 | USD | 90 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 328,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 57,000 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 2,878,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 958,000 | USD | 90 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -328,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | -57,000 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | -335,807,000 | USD | |
| At 2014-12-31 | -315,237,000 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 2,996,000 | USD | |
| At 2014-12-31 | 2,820,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 2,551,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 2,969,000 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -20,360,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | -17,322,000 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 56,501,000 | USD | |
| At 2014-12-31 | 73,732,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 11,626,000 | USD | |
| At 2014-12-31 | 13,620,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 2,383,000 | USD | |
| At 2014-12-31 | 2,549,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 20,360,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 17,322,000 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 14,504,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 11,628,000 | USD | 90 |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 383,512,000 | USD | |
| At 2014-12-31 | 378,007,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 130,000 | USD | |
| At 2014-12-31 | 130,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 945,000 | USD | |
| At 2014-12-31 | 1,057,000 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 5,856,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 5,694,000 | USD | 90 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -210,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | -216,000 | USD | 90 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -166,000 | USD | 90 |
| 2014-01-01 to 2014-03-31 | 2,238,000 | USD | 90 |
Inspect the source
- Entity
- HERON THERAPEUTICS, INC. /DE/ / CIK 0000818033
- Captured
- 2026-09-19T15:07:01.978Z
- SEC response SHA-256
8fd25ff077a16f81184199b9f7eb0d0d01ac0f8ba4c3b98a3b2cdfc2ad777b2a
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000818033.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))